Currently, there are multiple drugs targeting cyclins and cyclin-dependent kinases (CDKs) in clinical trials that provide potential for inhibiting cyclin E overexpression in endometrial cancers of Black patients [36,37]. The gene discussed is CCNE1; the disease is endometrial cancer.